Schrödinger Inc (NASDAQ:SDGR) shares dropped 13.7% following the company’s announcement that it is discontinuing development of its CDC7 inhibitor, SGR-2921, which was being evaluated in a Phase 1 study for leukemia patients.
The decision comes after two treatment-related deaths occurred in the Phase 1 dose-escalation trial involving patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes. While early monotherapy activity had been observed, the company concluded that advancing SGR-2921 as a combination therapy would be challenging due to safety concerns.
“Patient safety is our first priority, and in light of two treatment-related deaths in the Phase 1 study, we have made the decision to discontinue further development of SGR-2921,” said Margaret Dugan, M.D., Schrödinger’s chief medical officer.
Schrödinger had been optimistic about SGR-2921’s potential for AML, a disease characterized by high relapse rates, rapid progression, and limited treatment options. Preclinical studies had shown that CDC7 inhibition could produce anti-leukemic responses in patient-derived AML models.
Despite the early clinical activity observed, the company emphasized that discontinuing the program was the responsible course of action for patient safety.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.